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Background: Recurrent focal segmental glomerular sclerosis (rFSGS) in renal transplant
recipients (RTR) is difficult to predict and treat. Early rFSGS is likely from circulating factors
and preformed antibodies.
Methods:We present the case of a 23-year-old white man who presented with rFSGS and
acute renal failure, requiring dialysis 9-months after a 1-haplotype matched living-related
transplant. We retrospectively analyzed serum samples from various clinical stages for
rFSGS biomarkers: serum glomerular albumin permeability (Palb), soluble urokinase-type
plasminogen activator receptor (suPAR) serum level with suPAR-β3 integrin signaling on
human podocytes, and angiotensin II type I receptor-antibody (AT1R-Ab) titer.
Results: All biomarkers were abnormal at 1-year pre-transplant prior to initiation of dial-
ysis and at the time of transplant. After initiation of hemodialysis, β3 integrin activity on
human podocytes, in response to patient serum, as well as AT1R-Ab were further ele-
vated. At the time of biopsy-proven recurrence, all biomarkers were abnormally high.
One week after therapy with aborted plasmapheresis (secondary to intolerance), and
high dose steroids, the Palb and suPAR-β3 integrin activity remained significantly posi-
tive. After 12-weeks of treatment with high-dose steroids, rituximab, and galactose, the
patient remained hemodialysis-dependent. Three-months after his initial presentation, we
commenced adrenocorticotropic hormone (ACTH, Acthar® Gel), 80 units subcutaneously
twice weekly. Four-weeks later, he was able to discontinue dialysis. After 8-months of
maintenance ACTH therapy, his serum creatinine stabilized at 1.79 mg/dL with <1 g of
proteinuria.
Conclusion: ACTH therapy was associated with improvement in renal function within
4 weeks. The use of rFSGS biomarkers may aid in predicting development of rFSGS.
Keywords: acute kidney injury, albumin permeability factor, angiotensin 1 receptor antibody, podocyte, recurrent
focal segmental glomerular sclerosis, soluble urokinase plasminogen activator receptor
INTRODUCTION
Renal allograft loss due to recurrence of idiopathic focal segmen-
tal glomerular sclerosis (rFSGS) is common, with an incidence
of 30–50% (1–3). Recurrent FSGS has been reported within
1 week after transplant (4); and it has been hypothesized that a
circulating factor is responsible (5, 6). Injecting laboratory ani-
mals with serum from patients with FSGS caused proteinuria
and glomerular lesions reminiscent of FSGS (7). Serum from
FSGS patients induced increased glomerular albumin permeabil-
ity (Palb) in isolated glomeruli ex vivo (5). Savin et al. suggested
that the permeability factor is a 50 kD plasma protein (5), but
the nature of this Palb factor is still undefined. The approximate
50 kD sized serum soluble urokinase receptor (suPAR) is one of
the leading candidates. Elevated serum levels of circulating suPAR
(more than 3000 pg/dL) have been proposed to confer heightened
risk for rFSGS by inducing podocyte injury through activation
of β3-integrin (8). A recent report suggested antibodies to the
angiotensin II type 1 receptor (AT1R-Ab) may contribute to devel-
opment of rFSGS in renal transplant recipients (RTR) by causing
podocyte injury and severe podocyte foot process effacement (9).
Our patient presented with rFSGS. Therefore, we analyzed three
biomarkers in parallel and measured serum suPAR and the suPAR
beta3-integrin axis after incubation of human podocytes with the
patient’s sera, Palb, and AT1R-Ab serially in samples obtained 1-
year before transplant, at the time of transplant, when he was
admitted with rFSGS and acute kidney injury 9-months after
transplantation and 1- and 12-weeks after treatment.
Our patient did not respond or could not tolerate usual
methods of treatment for rFSGS. Adrenocorticotropic hormone
Acthar® (Acthar Gel, Questcor, Anaheim Hills, CA, USA) has been
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shown to induce complete or partial remission in a percentage of
patients with treatment-resistant FSGS in native kidneys, with 2 of
5 responders in one study and 8 of 24 responders in another (10,
11). We report the use of Acthar in this patient with rFSGS.
SUBJECTS AND METHODS
This study was approved by the Human Research Protection Office
(HRPO) of Washington University School of Medicine. A 23-
year-old white male with a history of end stage renal disease
(ESRD) secondary to FSGS presented 9-months after undergo-
ing a one-haplotype matched renal transplant on 24 July 2012
from his father with a low-grade fever consistent with a non-
descript viral illness, malaise, progressive edema, acute kidney
injury, and nephrotic range proteinuria. The complement depen-
dent cytotoxicity (CDC) and flow cross-match were negative
pre-transplant.
At the time of his transplant surgery, he had received thymo-
globulin 5 mg/kg over 3 days and was maintained on tacrolimus,
enteric coated mycophenolic acid (MPA), and prednisone. There
were no preformed donor specific antibodies. He developed low-
level cytomegalovirus (CMV)-viremia (Table 1) and leukopenia
4-months after transplantation, and his MPA was discontinued
and the valganciclovir (VGCV) dose increased from 450 to 900 mg
daily for treatment. Tacrolimus levels ranged 4–7 ng/mL. His
CMV-viremia resolved within 4 weeks (Table 1) and he was treated
with consolidation therapy with VGCV, 900 mg daily, which he was
still taking at presentation.
RESULTS
Nine-months after his renal transplant, he presented with ele-
vated serum creatinine from a baseline of 1.2–2.5 mg/dL. His 24-h
urine protein excretion revealed 10 g of proteinuria. There were
no donor specific antibodies identified by single antigen bead
assay (Luminex, One-lambda, Los Angeles, CA, USA). His blood
CMV-PCR was negative, and he had a normal renal transplant
sonogram.
A renal allograft biopsy demonstrated 19 glomeruli, one of
which was partially sclerosed and one was globally sclerosed
(Figure 1A). There was one medium size artery with no arteritis.
There was moderate arteriolar thickening. There was no tubulitis.
Periodic acid-Schiff and trichrome stains confirmed acute tubular
injury and highlighted minimal interstitial fibrosis. There was no
evidence of thrombotic microangiopathy. Immunofluorescence
staining was negative for C4d in peritubular capillaries. There
was no peritubular capillaritis. Electron microscopy showed exten-
sive foot process effacement and detached podocytes with reactive
cytoplasmic changes and villiform transformation (Figure 1B).
Abundant red blood cells (RBCs) were noted in the Bowman’s
space. The findings were consistent with rFSGS.
We analyzed stored blood samples from the Washington Uni-
versity Kidney Translational Research Core (NIH/NIDDK P30
DK079333) and tested for glomerular Palb (Savin Lab, Renal
Research, Kansas City Veterans Administration Medical Center,
Kansas City,MO,USA), suPAR,suPAR-beta3 integrin (β3 integrin)
signaling (Reiser Lab, U of ILL at Chicago, Chicago, IL, USA),
and angiotensin II type I receptor-antibody (AT1R-Ab) (Immuno-
genetics Laboratory, Johns Hopkins University, Baltimore, MD,
USA) on samples from 1-year pre-transplant, at the time of trans-
plant, and when the patient presented with acute kidney injury
(Table 1). To overcome a possible confounder of elevated serum
suPAR in the setting of reduced GFR, we also evaluated the activity
of β3 integrin signaling on cultured human podocytes incubated
with the patient’s sera. With this assay, strong integrin activa-
tion is indicative of the presence of pathologic suPAR forms, but
not physiologic or inflammatory suPAR that accumulated from
decreased clearance (12).
The levels of suPAR, suPAR-β3 integrin activation, and Palb
were elevated prior to transplant (3573 pg/mL, 1.63, and 0.77,
respectively) and at the time of recurrence (4691 pg/mL, 1.99, and
0.61, respectively). suPAR values >3500 pg/mL and β3 integrin
activity >1.3–1.5 are suggestive of suPAR-β3 integrin mediated
FSGS. A Palb of 0 is normal and values >0.5 designates an increased
risk (non-specific if between 0.2 and 0.5). The level of AT1R-Ab
was also increased prior to transplant, 20.4 U/mL, but was border-
line normal at 16.8 U/mL at the time of recurrence. AT1R-Ab is
presumed to be negative when <10, borderline when 10–17, and
positive when >17 (Table 2).
The patient was started on methylprednisolone 500 mg daily
for three days (Figure 2). Plasmapheresis with 1.5 plasma volume
exchanges with fresh frozen plasma followed by 10 g of IVIG the
day of his renal biopsy was attempted. However, shortly after com-
mencement, the patient developed wheezing, shortness of breath,
and an erythematous rash on his trunk, and extremities suggestive
of an allergic reaction, and plasmapheresis was discontinued. The
next day we attempted plasmapheresis with albumin, and again
the patient developed similar symptoms. We considered plasma-
pheresis with a hypoallergenic dialyzer column, but he refused
this treatment. We administered rituximab 200 mg intravenously,
once. This low-dose was chosen because of our experience with
efficacy with this dose for other recurrent glomerulonephritidies
and others have reported that even 100 mg can successfully treat
recurrent FSGS (13–16).
Five-days after the initial presentation, the patient became
anuric and he required hemodialysis (Figure 2). We initiated
lisinopril and arranged for outpatient hemodialysis. We attempted
to treat him with galactose (15 g of galactose twice a day for
6 weeks) in view of previously published data on possible ben-
efit (17, 18). Unfortunately, the galactose had to be discontinued
after 4-weeks due to severe diarrhea. He subsequently received
oral prednisone 100 mg daily as he had responded to a similar
dose during his previous four FSGS recurrences as a child prior
to his renal transplantation. At the end of 8-weeks, the patient
was still hemodialysis-dependent and the prednisone was gradu-
ally tapered to 10 mg daily over 2 months. We reassessed the three
circulatory factors. His Palb was 0.43 (0 is normal), his suPAR was
3447.9 pg/mL (negative< 3000 pg/mL, β3 integrin activity was
not available due to sample unavailability), and AT1R-Ab level
was 9.3 U/mL (negative< 10 U/mL).
Due to the significant side effects of prednisone, persistent
renal failure, and lack of efficacy, we initiated ACTH treatment
(Acthar® Gel,), 80 units twice weekly at 3.5-months after his initial
presentation (11). One-month after initiation of ACTH treatment,
the urine output increased, creatinine improved, and the patient
was able to discontinue dialysis. After 8-months on this therapy,
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Table 1 |Time course of clinical events, laboratory results and biomarkers.
1 year
pre-
transplant
At
transplant
1month
post-
transplant
3months
post-
transplant
4 months
post-
transplant
9months
post-
transplant
(admitted
with AKI)
1week after
admission
(after pulse
steroids
and one PE)
12months
post-
transplant
(2weeks before
starting ACTH)
15months
post-
transplant
(2.5months
on ACTH)
18months
post-
transplant
(5months
on ACTH)
28months
post-
Transplant
(8months after
ACTH therapy)
Creatinine (mg/dL) 4.09 HD 1.3 1.2 1.2 HD HD HD 2.9 2.3 1.83
FK trough (ng/mL) – – 6.4 6 5.8 – – 5.6 3.4 1.6 2.4
CMV PCR (copies/mL) – – – 4533 <200 <200 – – ND ND ND
BK virus PCR – – – ND – ND – – ND ND ND
Albumin (g/dL) 4.9 4.5 4.7 4.9 4.7 3.1 2.5 2.6 3.6 4.4 4.8
P/C ratio – – 0.09 – – 17.7 – – 7.2 2.2 0.34
DSA – ND – ND – ND – ND – – –
Palb 0.77 0.51 – – – 0.61 0.58 0.43 – – –
SuPAR (pg/mL) 3573 2898 – – – 4691 4428 3447.8 – – –
AT1R antibody (U/mL) 20.4 23.2 – – – 16.8 13.5 9.3 – – –
AKI, acute kidney injury; HD, hemodialysis; CMV, cytomegalovirus; IgG, immunoglobulin G; PCR, polymerase chain reaction; PE, plasma exchange; ND, not detected; FK, tacrolimus; P/C, protein to creatinine ratio;
DSA, donor specific antibodies; NA, not applicable; suPAR, soluble urokinase receptor.
Suspicious: >3000 pg/mL, values >3500 pg/mL are suggestive of suPAR-mediated FSGS (Dr. Reiser’s Lab, Rush University, USA). Palb: glomerular albumin permeability factor. Normal: 0. Nonspecific: 0.2–0.5.
Increased risk: >0.5 (Renal Research, KC VA Medical Center, Kansas City, MO, USA). Angiotension-1 receptor antibody: AT1Rab. Negative: <10. Borderline: 10–17. Positive: >17 (Immunogenetics Laboratory, The
Johns Hopkins University, Baltimore, MD, USA).
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FIGURE 1 | (A) Periodic acid-Schiff stain shows one partially sclerotic
glomerulus and two intact glomeruli; there is no tubulitis or interstitial fibrosis;
minor tubular epithelial cell changes are noted (×200). (B) Electron
microscopy shows foot process effacement (approximately 30% of the
surface area) and reactive cytoplasmic changes in podocytes. Numerous red
blood cells are present in the capillary loops and Bowman’s space (×3000).
Table 2 | Interpretation of putative markers in FSGS.
Soluble urokinase receptor: suPAR Normal: undetermined Intermediate risk:
>3000 pg/mL
Suggestive of suPAR-mediated FSGS:
>3500 pg/mL
Relative podocyte β3 integrin activity/paxillin
on human podocytes compared to control
(10% patient sera)
<1 Intermediate risk: >1 Highly suggestive of suPAR- β3 integrin
mediated FSGS: >1.5
Glomerular albumin permeability factor: Palb Normal: 0 Non-specific: 0.2–0.5 Increased risk: >0.5
Angiotension-1 receptor antibody: AT1Rab Negative: <10 U/mL Borderline: 10–17 U/mL Positive: >17 U/mL
FIGURE 2 |Time course of events, treatments, and responses in serum albumin and urine protein excretion.The serum albumin level over time is depicted
by the solid black line and the urine protein/creatinine ratio by the dashed gray line. The value at 40 weeks was imputed to be 0 because the patient was anuric.
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his creatinine decreased and remained stable at 2.0–2.5 mg/dL.
His serum albumin improved from 2.6 to 4.6 g/dL and his urine
protein-creatinine ratio decreased from 17.7 to 1.2. The ACTH
was discontinued. At last follow up, 28 months after transplant and
8 months after discontinuation of ACTH, the serum creatinine was
1.83 mg/dL, and a urine protein creatinine ratio was 0.34, and his
serum albumin is 4.8 mg/dL (Figure 2).
DISCUSSION
Various factors have been implicated as etiologic for rFSGS and
include suPAR (8), Palb (5), and AT1R-Ab (9). This case docu-
ments rFSGS in a renal transplant recipient in whom the levels
of suPAR- β3 integrin signaling, Palb, and AT1R-Ab were mea-
sured in combination and serially; starting from the pre-transplant
period through recurrence and follow up. At the time of trans-
plant, the Palb and AT1R-Ab and podocyte β3 integrin activity
were elevated, which means that podocyte β3 integrin was ele-
vated in focal adhesions (represented by paxillin staining), the
contact points of podocytes with the extracellular matrix (12).
These biomarkers identified the patients as high risk for rFSGS
despite the fact that he remained recurrence free for the first 9-
months following his transplant. It will require further studies to
understand why the patient was disease free for the first 9-months
after transplant. The use of rabbit anti-thymocyte globulin (rATG)
for induction may have contributed as rATG has been associated
with less rFSGS (19). Of note, rabbit-ATG is no longer detectable
in blood 6–9 months after administration – the time of the recur-
rence in the face of persistently high putative biomarkers for rFSGS
(20).
The role of suPAR in proteinuric renal disease is currently under
active investigation (21). It may be possible that suPAR plays a role
in both genetic and non-genetic forms of rFSGS (9); even so rFSGS
is generally less prominent in genetic forms of FSGS (8). Some
reports show inconsistencies in associations of suPAR and rFSGS
in patients with advanced CKD and reduced eGFR in pediatric
(22, 23) and adult FSGS patients (24).
Some of the inconsistencies between reports may be related to
the quality of the stored samples and the availability of all relevant
clinical information including renal biopsy. It is also likely that
different suPAR fragments exist and that all of those may not be
readily measured with current ELISA, and thus the need to detect
the activating capacity of suPAR at the level of the podocyte. In
addition, urinary suPAR was recently shown to be highly specific
for FSGS and FSGS-urine strongly activated β3 integrin on human
podocytes (25, 26). In the future, urinary suPAR measurements in
urine may provide valuable information in assaying the suPAR
forms that are most relevant to FSGS.
Savin et al. reported a method to test for increased glomerular
capillary permeability after incubation with potentially injurious
agents or with medium containing 2% vol/vol patient serum. The
permeability activity (termed Palb activity or Palb) is used to infer
the presence of a circulating factor. Palb is calculated from the ratio
of capillary expansion of experimental and control glomeruli. Val-
ues range from 0, indicating no activity, to 1, indicating complete
loss of the permeability barrier. Values >0.5 have been associated
with a high incidence of rFSGS following RTR (5). This perme-
ability factor has a high affinity for galactose and Palb activity was
lost after galactose infusion in a RTR with rFSGS (17).
Our patient had elevated AT-1R Abs throughout his course.
Podocytes express AT-1R (27, 28), and antibodies against the
AT1R have been hypothesized to play a role in many kidney
diseases. They have been shown to be elevated in vascular rejec-
tion (29), pre-eclampsia (30), and systemic sclerosis (31). The
elevated levels suggest a possible role of AT1R-Ab in podocyte
injury. In one case report of rFSGS, AT1R-Ab level was elevated
and the patient was treated successfully with plasmapheresis and
angiotensin converting enzyme inhibitors (ACEI) (9). While the
clinical improvement of the patient after plasmapheresis suggests
removal of antibodies, it does not prove the pathogenicity of
AT1R-Ab in this case.
Our report provides valuable insights into the use of ACTH
to treat rFSGS. Adrenocorticotropic hormone is a drug which
has been approved for infantile spasms, but also carries the indi-
cation for nephrotic syndrome (32). Its use in renal transplant
patients has not been reported for recurrent nephrotic syndrome.
Although not completely defined, ACTH, either alone or via
its breakdown product α-melanocyte-stimulating hormone, may
induce a potent anti-inflammatory effect by reducing B- and T-
cell activity and may also have a direct, podocyte-sparing effect
within the glomerulus (33). This would be consistent with the
observation that serum suPAR and the integrin activation profile
were decreasing. We were able to discontinue the ACTH after 8-
months of therapy without evidence of recurrence 8-months after
discontinuation.
There are several limitations to our study. The study is retro-
spective and based on stored serum samples. As such, some level
of sample deterioration is possible. We also did not have sufficient
serum to assess our complete biomarker panel between transplant
and recurrence and we did not have samples for biomarker assess-
ment at the time of ACTH effectiveness. Lastly, we cannot validate
the sensitivity, specificity, and variability of these assays.
In conclusion, this case of rFSGS suggests that elevated suPAR-
β3 integrin signaling, Palb, and AT1rab levels at pre-transplant
confer an increased risk of developing rFSGS. This risk assessment
is consistent with previously reported studies (12). However, the
case also demonstrates the difficulty in understanding the precise
cause as well as the course of rFSGS. Our patient developed recur-
rence 9-months later when serum suPAR increased by more than
50%. This could have been the initiating injury that caused a point
of no return for podocyte injury.
Measuring suPAR and Palb levels in young transplant recipi-
ents with a history of FSGS in their native kidneys and/or when
planning for living transplants might provide additional informa-
tion to develop immunosuppression strategies and to optimize
post-transplant monitoring.
Adrenocorticotropic hormone therapy provides transplant
physicians with an additional therapeutic option for proteinuric
kidney disease. Given the success in this case, the relationship of
adrenocorticotropic hormone therapy and suPAR needs to be bet-
ter defined on a molecular level as well as in controlled trials,
possibly as an ad hoc to the trial currently underway for transplant
glomerulopathy (34).
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